Abstract: Limits for measurement uncertainty related to analytical imprecision and bias are most appropriately defined by the magnitude of tolerable diagnostic errors. A common mean to characterize the consequence of these errors is the diagnostic efficiency, which, in the case of data from a non-diseased population, is the rate of true-positive results (specificity). Three models have been identified by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) for defining permissible uncertainty limits. Their model 1 is based on diagnostic requirements whereas models 2 and 3 do not primarily consider diagnostic errors. The present report links tolerable diagnostic error, empirical biological variation and the technical state of the art to derive the limits for measurement uncertainty. This approach combines the essential aspects of all three EFLM models and uses the diagnostic error, the clinically most relevant aspect, as the crucial criterion for the characterization of measurement uncertainty limits. The present approach is designed for the sole purpose of quality assurance.
Introduction
According to the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) hierarchy developed at two conferences in Stockholm (1999) and in Milan (2015) , permissible uncertainty limits can be derived from clinical outcome, biological variation (BV) and the state of the art [1, 2] . All three models have their merits. Model 1 has the advantage of being based on diagnostic requirements, but the disadvantage that it usually addresses only one clinical situation.
For model 2, Harris [3] proposed defining permissible imprecision by multiplying BV by a factor of 0.5. The major disadvantage of this proposal is that the resulting limits are unrealistically narrow for measurands with small BVs (respective reference range) and too permissive for measurands with relatively large BVs. Fraser [4] tried to circumvent this drawback by suggesting three factors (0.25, 0.5 and 0.75). However, even this is not adequate to the real situation because of jumps in the size of resulting permissible uncertainties between the three classes induced by the factors. As has been demonstrated [5] , a smooth nonlinear relationship between permissible measurement uncertainty and BV appears much more appropriate.
Model 3 is primarily based on technical feasibility, independent of clinical needs.
Although model 1 is at the top of the EFLM hierarchy, it does not make sense to establish limits for quality assurance by this approach if those limits cannot be reached by the best present technology (state of the art).
In a recent proposal [5] , we tried to reconcile model 2 with model 3, using BV as the starting criterion. In this report, we introduce the diagnostic error, quantified by the rate of false-positive results (FPRs, non-specificity) to characterize the permissible uncertainty. The diagnostic (non-)efficiency is the information which is of major interest for physicians requesting laboratory services.
Defining the permissible measurement uncertainty based on reference intervals
Before turning toward the characterization of permissible uncertainty on the basis of FPR, we summarize the estimation of permissible uncertainty based on BV, because some of the equations for this definition are also needed for the characterization of the approach.
Most earlier concepts, e.g. the total analytical error concept [6] or the RiliBAEK by the German Medical Association [7] , assume a constant permissible uncertainty within the measurement interval. Recently, we have pointed out that analytical uncertainty is never constant in the measurement interval [5] . Instead, we assume a power function for the relation between the (constant) coefficient of variation (CV) of the empirical BV E (CV ) * and the CV of the permissible analytical imprecision (pCV A ):
In this equation, the empirical BV E CV , * as a surrogate for the BV, is derived from the reference interval in analogy to the well-known Tonks's rule [8] . Doing this, we assume here and in the sequel a log-normal distribution of the reference values, because the true distribution of reference values is in most cases unknown and the log-normal distribution is a sensible general assumption. The relation in eq. (1) accounts for the actual state of the art with regard to the realistic analytical imprecision and avoids artificial jumps like those introduced by Fraser [4] . From eq. (1) the permissible standard deviation at the median (MED) is obtained as [5] :
With this standard deviation, the permissible analytical standard deviation, ps A,xi , at each measured value x i is calculated by [9, 10] 
with a corresponding CV,
The relative permissible bias (pB%), expressed as a percentage of x i , was postulated [5] 
The derivation of eqs. (1-6) has been described elsewhere in detail [5, 9, 11] .
A simplified approach to quality assurance by neglecting bias Imprecision and bias have different and complex effects on the rates of FPRs. The FPR is much more affected by bias than by imprecision [4, [12] [13] [14] [15] . If imprecision and bias have the same numerical value on a scale of measurement, the effect of bias only on FPR is larger than the effect of imprecision only. A correct algorithm to quantify the combined effect of imprecision and bias requires good knowledge of the process generating the bias, which is not usually available. Therefore, the ideal solution is to avoid bias [13] . Several concepts of analytical bias and remedies to minimize bias have been suggested with the ultimate goal being to neglect it [5, 13] . Short-term bias (within one control cycle) should be treated as a random error if it is less than the permissible limits. Long-term bias (within several control cycles) should be eliminated if it is known or circumvented by estimating the intra-laboratory reference limits or by verifying the applied reference limits (checking the transferability) as requested by the Clinical and Laboratory Standards Institute (CLSI) [16] . Consequently, analytical uncertainty could be reduced to a permissible imprecision. Then, models combining imprecision and bias would become irrelevant, and the numerical value of total analytical error would become identical with imprecision [13] .
If bias is neglected, permissible quality assurance limits (PL) can be defined as 1 A ,xi PL mean z ps . = ± ⋅
In eq. (7), mean 1 is the average of replicate measurements during the first control cycle of a control period (or a cumulative of, e.g. the first 3n control cycles) and z is set to 1.96 to obtain an approximate 95% confidence interval. A control period usually is defined by the "lifetime" of a control material batch. Target values are not required for internal quality assurance in the simplified concept; however, their importance remains for external quality assurance and for estimating the amount of bias if it is detected. In a common example, target value and pCV A recommended by the manufacturer can be applied for the first control cycle (RiliBAEK: "Ermittlungsperiode") of a control material batch. After the first control cycle (about 20 days), the mean of the replicate control sample values from the first cycle is calculated. A control chart is constructed with the mean and the control limits [eq. (7)]. The control charts of the following control cycles always use the mean of the previous cycle. If a new lot of the control material is started, it is common practice to overlap the first control cycle with the last cycle of the previous lot [11] . This example can be modified according to the internal requirements.
Results

Assessing the diagnostic efficiency by FPRs
In laboratory medicine, the outcome of laboratory examinations may be characterized by the diagnostic efficiency which could serve as a surrogate for clinical success. The diagnostic efficiency of examinations in laboratory medicine can be judged from the number of truepositive and true-negative results or correspondingly the non-efficiency from the number of FPRs and falsenegative results [12] . In analogy, the efficiency of quality assurance schemes may be judged from the rate of FPRs and/or false-negative results.
Reference intervals (RIs) are usually defined as an interval of the measurement range which covers the inner 95% of values from a reference population allowing 2.5% of FPRs on each side of the distribution [16] . RI do not consider results from diseased persons (which usually do not belong to the reference population). Therefore, only FPRs can be considered. The shaded zone in Figure 1 shows the range of false-positive decisions in the upward direction. We assume throughout that false-positive decisions are only clinically relevant if they occur in this direction.
An increase of imprecision ( Figure 1 ) or of bias without correction of the RI (Figure 2 ) results in increasing rates of FPRs. The increase of FPRs (ΔFPR) is indicated by the black area in Figures 1 and 2 .
Assuming a log-normal distribution of the reference data (as explained above), ΔFPR can be calculated in the following way at the upper RL (RL 2 ):
In this equation, F means the log-normal distribution function and the terms ln M′′ and E,ln s′′ are the parameters of the log-normal distribution that hold under the presence of additional imprecision or bias. Their calculation is given in the Appendix. ΔFPR values for selected measurands are presented in Table 1 . A part of this table has already been shown in Ref. [5] , it is extended here by column I (ΔFPR). The complete table with 70 plasma measurands is presented in Ref. [15] . A non-linear relation between pCV A,xi and ΔFPR is shown in Figure 3 , and between E CV * and ΔFPR in Figure 4 .
For the purpose of quality assurance, ΔFPR can be considered as a surrogate measure for clinical outcome independent of the clinical situation. A ΔFPR of 0.5% or less is observed for about 64% of the measurands listed in the RiliBAEK (green cells in column I of be desirable even in the absence of bias. However, this is probably difficult to achieve with the present technologies. Therefore, instead of fixed rates of ΔFPR, a non-linear relationship more appropriately describes the present situation.
The classification in the three groups is arbitrary. The green group somehow corresponds to Fraser's "optimal" class of measurands [4] , the yellow group to the "desirable" class and the blue group to the "acceptable" class. The relation between permissible uncertainty [determined by eq. (1)] and ΔFPR is curved and not linear (Figure 3) . The permissible uncertainty for measurands with a relatively low BV (e.g. plasma sodium) leads to a higher ΔFPR than measurands with a relatively high BV. Five measurands (of the complete Table 1 ) had a ΔFPR above 1.0: calcium (1.3%), ionized calcium (1.0%), chloride (2.1%), pH (2.0%) and sodium (2.9%).
Characterization of uncertainty limits by FPRs
Three examples ( with a large BV E (CV * = 32.8). The permissible analytical standard deviation is referred to the corresponding measured value x i using eq. (3). The root-mean-square deviation (RMSD) values (see Table 1 ) are assumed to cover about 95% of the routine laboratories. Assuming a normal distribution, the RMSD can be divided by 1.96 to provide the theoretical pCV A (bias = 0) or the theoretical permissible bias (pCV A = 0). In practice, more often a situation may occur between these two extreme situations when imprecision and bias are jointly present.
The ΔFPR value for plasma calcium is 1.3% with the simplified model. This value may be considered acceptable, but should be improved. Within the RiliBAEK limits, the ΔFPR value varies between 3.1% and 4.2% (Table 2 ).
The glucose RI chosen from the literature [18] is 3.9-6.4 mmol/L (70-115 mg/dL). At the upper reference limit, a ΔFPR of 0.6% was found ( Table 2) . With the RiliBAEK limit [7] of 11% (corresponding to a pCV A of 11/1.96 = 5.61), ΔFPR% varied between 1.7% (no bias) and 4.2% (no increased imprecision). Assuming that both error types share the same size, ΔFPR% was 3.8. The permissible interval of the RiliBAEK at 6.4 mmol/L (=±0.7 mmol/L; ±13 mg/dL) is probably too large for diagnostic purposes and lead to unacceptably high ΔFPR values. On the contrary, the pCV A of about 3.4% at 6.4 mmol/L for the simplified model (ΔFPR = 0.61%) can be achieved by most medical laboratories using an automated hexokinase procedure. A ΔFPR of <1.0% is transparent, easily understandable and independent of expert opinions. A comprehensive study on EFLM model 1 may not be further required.
The ΔFPR for aspartate aminotransferase is about 0.4% under the conditions chosen for the present proposal. Within the RiliBAEK limits, the ΔFPR value varies between 0.5% and 1.4%. Assuming that both error types share an equal percent value, ΔFPR% is 1.2.
These data clearly demonstrate that a combination of imprecision with bias with unidentified proportions is critical. The ΔFPR value can reach unacceptably high values if bias becomes the dominating error especially in measurands with a low BV. 
Discussion
Whereas proposals for permissible uncertainty are required for daily quality assurance, they usually do not address the diagnostic efficiency. Physicians are probably more interested in the limits defined by diagnostic efficiency (as a measure of clinical outcome) than in the fractions of BV. Figure 3 clearly demonstrates a non-linear relation existing between FPR and the measurement uncertainty (as shown for the imprecision). Measurands with a relatively small BV have a lower diagnostic specificity (blue zone) than measurands with a relatively large BV (green zone). These measurands, although with acceptable non-specificity, require further improvements. The rate of FPRs can serve as an indicator for the diagnostic utility of a test, especially in comparison with other tests (Figure 3) .
The major problem of the classical concept of Harris [3] and the later proposals of Fraser et al. [4, 19] is that one or several fixed factors for multiplying BV data do not correctly reflect the technical feasibility. The relation between the BV and the analytical variation is rather curved than linear [5] .
The present proposal interrelates the three EFLM models: diagnostic efficiency (as an outcome measure), BV and the technical feasibility. Furthermore, it is consistent with the GUM approach [20] .
Equations (1-17) can be solved on an excel spread sheet. A version that automatically calculates the permissible uncertainty and the ΔFPR values is gratuitously available on the home page of the DGKL [17] .
Conclusions
Contrary to model 1, model 2 and 3 of the EFLM proposal provide permissible limits for the measurement uncertainty without relation to clinical outcomes. However, if these models are related to the rate of FPRs (ΔFPR), their diagnostic efficiency becomes evident. This effect has been shown for the concept combining the EFLM models 2 and 3. Although the three groups corresponding to the different ranges of ΔFPR have been arbitrarily suggested, the relation between analytical uncertainty (Figure 3 ) and the size of ΔFPR is non-linear.
The lower the BV and consequently the E CV * value (as a surrogate for BV), the permissible analytical variation (pCV A ) and consequently the ∆FPR become higher. An inverse relation exists between pCV A and ∆FPR. The combination of imprecision and bias leads to variable ∆FPR values, which becomes unacceptable if the bias value is relatively high in relation to the imprecision as allowed in the latest RiliBAEK. 
In eq. (15), ps A is the permissible analytical error. The combination of s A , resp. CV A with E CV * leads to a circular reasoning. However, the argument can be neglected if the analytical variation is small in relation to the BV. This is the case for most measurands in clinical chemistry. With plasma sodium (a quantity with a relatively small BV), the pCV A derived by the present proposal is equal to the permissible limit of the RiliBAEK [11] .
